ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey Sells 7,500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ANI Pharmaceuticals Price Performance

ANIP traded down $1.95 during midday trading on Wednesday, reaching $53.88. 198,776 shares of the company’s stock were exchanged, compared to its average volume of 221,746. The business’s 50-day moving average price is $58.00 and its 200 day moving average price is $60.17. The stock has a market capitalization of $1.13 billion, a PE ratio of -97.96 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a 1-year low of $52.00 and a 1-year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter last year, the business posted $1.05 earnings per share. ANI Pharmaceuticals’s revenue was up 12.5% compared to the same quarter last year. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after acquiring an additional 9,500 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $228,000. Thompson Siegel & Walmsley LLC increased its stake in ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after purchasing an additional 34,416 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after buying an additional 299 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in ANI Pharmaceuticals by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company’s stock worth $9,985,000 after buying an additional 20,900 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Truist Financial raised their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. Raymond James raised their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.